|Bid||78.32 x 900|
|Ask||79.00 x 900|
|Day's Range||78.21 - 79.31|
|52 Week Range||65.25 - 92.64|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||19.97|
|Earnings Date||Jul 31, 2020|
|Forward Dividend & Yield||2.44 (3.10%)|
|Ex-Dividend Date||Jun 12, 2020|
|1y Target Est||93.00|
A look at the shareholders of Merck & Co., Inc. (NYSE:MRK) can tell us which group is most powerful. Institutions...
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. We are almost done with the second quarter. Investors decided […]
Wall Street is moving some bets on COVID-19 vaccines to large pharmaceutical companies with robust manufacturing capabilities, signaling that a love affair with small biotech firms might be ending after the sector’s best quarter in almost 20 years. Early signs of the shift came Wednesday, when positive data for one of Pfizer Inc’s COVID-19 vaccine candidates sent shares of the large U.S. drugmaker up more than 3%. Although the news had little effect on shares of Pfizer’s large rivals in the vaccine race, smaller peers Moderna Inc and Inovio Pharmaceuticals Inc, both of which have previously shown promising COVID-19 data of their own, ended down more than 4% and 25%, respectively.